These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 23640069)

  • 1. Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?
    Mims A; Stuart RK
    Curr Hematol Malig Rep; 2013 Jun; 8(2):156-62. PubMed ID: 23640069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
    Roskoski R
    Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is targeted therapy feasible in acute myelogenous leukemia?
    Konig H; Levis M
    Curr Hematol Malig Rep; 2014 Jun; 9(2):118-27. PubMed ID: 24599573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutics in acute myeloid leukemia.
    Sweet K; Lancet JE
    Curr Hematol Malig Rep; 2014 Jun; 9(2):109-17. PubMed ID: 24633743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.
    Kim M; Williams S
    Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
    Garcia JS; Stone RM
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy options for previously untreated acute myeloid leukemia.
    Lynch RC; Medeiros BC
    Expert Opin Pharmacother; 2015; 16(14):2149-62. PubMed ID: 26364895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
    Daver N; Cortes J; Kantarjian H; Ravandi F
    Expert Rev Hematol; 2016 May; 9(5):433-45. PubMed ID: 26910051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLT3 inhibitors for acute myeloid leukemia.
    Lancet JE
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):573-5. PubMed ID: 26452187
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug development: target practice.
    Katsnelson A
    Nature; 2013 Jun; 498(7455):S8-9. PubMed ID: 23803950
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic targeting of FLT3 and associated drug resistance in acute myeloid leukemia.
    Gebru MT; Wang HG
    J Hematol Oncol; 2020 Nov; 13(1):155. PubMed ID: 33213500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
    Fernandez S; Desplat V; Villacreces A; Guitart AV; Milpied N; Pigneux A; Vigon I; Pasquet JM; Dumas PY
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
    Pemmaraju N; Kantarjian H; Ravandi F; Cortes J
    Cancer; 2011 Aug; 117(15):3293-304. PubMed ID: 21319142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatment for acute myelogenous leukemia.
    DiNardo CD; Cortes JE
    Expert Opin Pharmacother; 2015 Jan; 16(1):95-106. PubMed ID: 25480777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protein Kinase Inhibitors as Therapeutic Drugs in AML: Advances and Challenges.
    Ling Y; Zhang Z; Zhang H; Huang Z
    Curr Pharm Des; 2017 Nov; 23(29):4303-4310. PubMed ID: 28671056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New drug approvals in acute myeloid leukemia: an unprecedented paradigm shift.
    Kopmar NE; Estey EH
    Clin Adv Hematol Oncol; 2019 Oct; 17(10):569-575. PubMed ID: 31730583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia.
    Watt TC; Cooper T
    Pediatr Blood Cancer; 2012 Oct; 59(4):756-7. PubMed ID: 22052552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
    Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.